Consensus Surgery Partners, Inc.

Equities

SGRY

US86881A1007

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
25.39 USD +3.89% Intraday chart for Surgery Partners, Inc. -1.70% -20.63%

Evolution of the average Target Price on Surgery Partners, Inc.

Price target over the last 5 years

History of analyst recommendation changes

18f05d5eabc6f2d3dc8ee59fef.mVEcsc0mxAOOVdVXmUyl_2xuB1DcBbeeTkfnqy42rgg.rihQ7oFemzbRGaAy9zXSmRsDXwLxWvb1PXeymgN8zHz-P0nAi0SrecUW7Q~a6d3760c04bda2fe523f199bb57ddc08
RBC Raises Price Target on Surgery Partners to $49 From $47, Keeps Outperform Rating MT
Optimism Over Potential Upcoming Interest Rate Cuts Drives Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday MT
TD Cowen Upgrades Surgery Partners to Outperform From Market Perform, Cuts Price Target to $35 From $39 MT
Barclays Adjusts Price Target on Surgery Partners to $51 From $56, Maintains Overweight Rating MT
Mizuho Adjusts Price Target on Surgery Partners to $50 From $48, Maintains Buy Rating MT
BofA Securities Upgrades Surgery Partners to Buy From Neutral, Adjusts Price Target to $45 From $42 MT
Mizuho Starts Surgery Partners at Buy With $48 Price Target MT
Citigroup Adjusts Price Target on Surgery Partners to $47 From $40, Maintains Buy Rating MT
Cantor Fitzgerald Initiates Surgery Partners at Overweight With $43 Price Target MT
RBC Trims Price Target on Surgery Partners to $47 From $48, Maintains Outperform Rating MT
Barclays Adjusts Price Target on Surgery Partners to $56 From $69, Maintains Overweight Rating MT
Benchmark Adjusts Price Target on Surgery Partners to $47 From $60, Maintains Buy Rating MT
RBC Cuts Price Target on Surgery Partners to $48 From $58, Citing Pro Forma Capital Structure, Maintains Outperform Rating MT
SVB Securities Adjusts Price Target on Surgery Partners to $40 From $55, Maintains Outperform Rating MT
SVB Securities Adjusts Price Target on Surgery Partners to $55 From $57, Maintains Outperform Rating MT
RBC Cuts Price Target on Surgery Partners to $58 From $62, Noting Sequentially Higher Net Debt, Maintains Outperform Rating MT
Citigroup Cuts Price Target on Surgery Partners to $38 From $49, Maintains Buy Rating MT
RBC Cuts Price Target on Surgery Partners to $62 From $65, Maintains Outperform Rating MT
BofA Securities Downgrades Surgery Partners to Neutral From Buy MT
SVB Leerink Adjusts Surgery Partners' Price Target to $65 from $63, Keeps Outperform Rating MT
RBC Adjusts Price Target on Surgery Partners to $65 From $70, Citing Higher Share Count, Maintains Outperform Rating MT
SVB Leerink Adjusts Surgery Partners' Price Target to $63 from $61, Keeps Outperform Rating MT
SVB Leerink Adjusts Surgery Partners' Price Target to $61 from $52, Keeps Outperform Rating MT
Barclays Starts Surgery Partners at Overweight With $73 Price Target MT
Stifel Upgrades Surgery Partners to Buy From Hold; Price Target is $51 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
25.39 USD
Average target price
41.09 USD
Spread / Average Target
+61.84%
High Price Target
50 USD
Spread / Highest target
+96.93%
Low Price Target
35 USD
Spread / Lowest Target
+37.85%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Surgery Partners, Inc.

RBC Capital Markets
TD Cowen
Barclays
Mizuho Securities
BofA Securities
Citigroup
Cantor Fitzgerald
Benchmark Company
SVB Securities LLC
SVB Leerink
Stifel Nicolaus
JPMorgan Chase
Cowen
UBS
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock Market
  2. Equities
  3. SGRY Stock
  4. Consensus Surgery Partners, Inc.